Grant: Master's Award: Canada Graduate Scholarships
Université de Sherbrooke
$17,500.00
Does pre-gestational type 1 or type 2 diabetes lower omega-3 fatty acids in the cord blood of new borns and thus interfere with neurodevelopment?
FY 2018-19
Summary
Docosahexaenoic acid (DHA) is a long-chain polyunsaturated fatty acid that is essential for healthy brain and nervous system development during pregnancy. During the third trimester, maternal lipolytic activity is increased in order to meet the fetus’s increased need for DHA. A deficiency in DHA at this time could be detrimental to the neurodevelopment of the fetus. Previous studies have shown that pregnant women with type 1 or type 2 diabetes (T1D or T2D), also known as pre-gestational diabetes (PGD), have lower levels of DHA in their red blood cells. It has also been observed that in diabetic pregnancies, less DHA is present in the umbilical cord blood compared to non-diabetic pregnancies and that DHA may be accumulated in the placenta instead of being released into the cord blood. In this project, we will explore the link between fatty acids in newborns and T1D and T2D mothers and neurological measurements in the babies. We hypothesize that PGD mothers have a placental defect that alters the transfer of DHA to the cord blood and this will result in lower neurodevelopment of the occipital brain region. We also hypothesize that the neurodevelopment of the newborn is positively correlated with DHA concentrations in the cord blood. We will evaluate the fatty acid profile of maternal plasma, cord blood, and the placenta using gas chromatography. Moreover, we will assess the expression of various placental fatty acid transporters using Western Blot and mass spectrometry. Finally, we will evaluate the neurodevelopment of the newborns using electroencephalography (EEG) 24-48 hours after birth and at 2 months of age. The results of this project will help us to better understand the impact that PGD may have on the fatty acid status and the neurodevelopment of newborns.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406534
Name
Chappus-McCendie Hillary M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Does pre-gestational type 1 or type 2 diabetes lower omega-3 fatty acids in the cord blood of new borns and thus interfere with neurodevelopment?
Programtype2
Studentship Programs
Orgnameinp2
Université de Sherbrooke
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Diabetes; Electroencephalography; Neurodevelopment; Omega-3 Fatty Acids; Placental Transfer; Pregnancy
Abstract
Docosahexaenoic acid (DHA) is a long-chain polyunsaturated fatty acid that is essential for healthy brain and nervous system development during pregnancy. During the third trimester, maternal lipolytic activity is increased in order to meet the fetus’s increased need for DHA. A deficiency in DHA at this time could be detrimental to the neurodevelopment of the fetus. Previous studies have shown that pregnant women with type 1 or type 2 diabetes (T1D or T2D), also known as pre-gestational diabetes (PGD), have lower levels of DHA in their red blood cells. It has also been observed that in diabetic pregnancies, less DHA is present in the umbilical cord blood compared to non-diabetic pregnancies and that DHA may be accumulated in the placenta instead of being released into the cord blood. In this project, we will explore the link between fatty acids in newborns and T1D and T2D mothers and neurological measurements in the babies. We hypothesize that PGD mothers have a placental defect that alters the transfer of DHA to the cord blood and this will result in lower neurodevelopment of the occipital brain region. We also hypothesize that the neurodevelopment of the newborn is positively correlated with DHA concentrations in the cord blood. We will evaluate the fatty acid profile of maternal plasma, cord blood, and the placenta using gas chromatography. Moreover, we will assess the expression of various placental fatty acid transporters using Western Blot and mass spectrometry. Finally, we will evaluate the neurodevelopment of the newborns using electroencephalography (EEG) 24-48 hours after birth and at 2 months of age. The results of this project will help us to better understand the impact that PGD may have on the fatty acid status and the neurodevelopment of newborns.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chappus-McCendie, Hillary M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~